Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

Here are two stocks with buy rank and strong value characteristics for investors to consider today, April 23:Phio Pharmaceuticals Corp. (PHIO) : This immuno-oncology biotech company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 14.4% over the last 60 days.Phio Pharmaceuticals has a price-to-earnings ratio (P/E) of 0.66 compared with 7.20 for the industry. The company possesses a Value Scoreof B.Transportadora de Gas del Sur S.A. (TGS) : T ...

Core Insights - Genenta Science, a leader in immuno-oncology and cell-based therapeutics, is advancing its pipeline with a strategic financing of €20 million ($22.7 million) through a Mandatory Convertible Bond to ENEA Tech and Biomedical [2] - The company is focused on the development of Temferon™ for metastatic Renal Cell Cancer (mRCC) and has raised an additional €3.0 million ($3.2 million) via an at-the-market facility [2] - CEO Pierluigi Paracchi will present at the "Montalcini Global Biotech Tour" in Doha, Qatar, highlighting the Italian biotech ecosystem and the company's initiatives [1][3] Company Developments - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients, indicating potential for reprogramming the tumor microenvironment [6] - The company has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will explore combinations with immune checkpoint inhibitors [6] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, aiming for a durable and targeted response [6] Strategic Partnerships - The event in Doha will feature key stakeholders, including representatives from the Qatar Investment Authority, which manages over $475 billion in assets, indicating potential for cross-border partnerships [4] - CDP Venture Capital, a long-standing investor in Genenta, participated in the company's IPO on Nasdaq in 2021, showcasing ongoing support from institutional investors [3]

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][4] - Dr. Jeffrey Miller from the University of Minnesota will present at the 10th Anniversary of the Innate Killer Summit, discussing the advantages of tri-specific engagers in enhancing NK cell activity [2] Company Developments - GTB-3650, a second-generation TriKE, is currently in a Phase 1 dose escalation study for patients with hematological malignancies, with enrollment proceeding as expected [3] - The study will evaluate GTB-3650 in approximately 14 patients with relapsed or refractory CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome [3] - Initial data from the GTB-3650 study is anticipated to be shared in 2025 [3] Technology and Collaboration - The TriKE platform is designed to enhance the cancer-killing abilities of natural killer cells in patients [4] - GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using TriKE technology [4]